Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2024-05-08Clinical Trial Update: STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS [Phase 2]
Phase 2 trial comparing three ixazomib-based regimens (ixazomib with dexamethasone; ixazomib with cyclophosphamide and dexamethasone; ixazom…
-
CLINICAL_TRIALS trial_result · 2024-05-08Clinical Trial Update: The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
This clinical trial update indicates the study on risk stratification in multiple myeloma using fluorescence flow cytometry to quantify circ…
-
CLINICAL_TRIALS research · 2024-05-07Clinical Trial Update: ASCT With Nivolumab in Patients With Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update reports a Phase 1/2 study evaluating autologous stem cell transplantation augmented with nivolumab in patients wi…
-
CLINICAL_TRIALS withdrawal · 2024-05-06Clinical Trial Update: Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M) [Phase 2]
A Phase 2 MATCH subprotocol trial testing nivolumab with relatlimab (BMS-986016) for LAG-3 positive tumors with mismatch repair deficiency h…
-
FDA approval · 2024-05-03FDA Approved: PLERIXAFOR — Original Application (Gland Pharma Limited)
FDA approved an original application for a generic version of plerixafor (ANDA206644) from Gland Pharma Limited for stem cell mobilization i…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2024-05-03Clinical Trial Update: Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
A clinical trial update describing the recruitment status for evaluating clinical pathways in newly diagnosed multiple myeloma patients.
-
FDA approval · 2024-05-03FDA Approved: BORTEZOMIB — Original Application (Camber Pharmaceuticals, Inc.)
FDA approves Camber Pharmaceuticals' generic Bortezomib through an Original Application (ANDA 212204). This approval makes a generic version…
-
CLINICAL_TRIALS withdrawal · 2024-05-01Clinical Trial Update: CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]
A Phase 1 clinical trial evaluating CART-BCMA/CS1 for relapsed or refractory multiple myeloma has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2024-04-30Clinical Trial Update: Daratumumab, Azacitidine, and Dexamethasone for Treatment of Patients With Recurrent or Refractory Multiple Myeloma Previously Treated With Daratumumab [Phase 2]
Phase 2 trial evaluating daratumumab, azacitidine, and dexamethasone for recurrent or refractory multiple myeloma previously treated with da…
-
CLINICAL_TRIALS withdrawal · 2024-04-26Clinical Trial Update: Mycobiome Supporting Diet to Reduce GI Toxicity Associated With ASCT [NA]
A clinical trial evaluating a mycobiome-supported diet to reduce GI toxicity during autologous stem cell transplant for multiple myeloma has…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region) [Phase 3]
Phase 3 trial comparing VELCADE-melphalan-prednisone vs Daratumumab with VMP in previously untreated multiple myeloma in the Asia-Pacific re…
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma [Phase 1]
A Phase I safety, pharmacokinetic and pharmacodynamic study of KW-2478 in patients with multiple myeloma, chronic lymphocytic leukemia, or B…
-
CLINICAL_TRIALS research · 2024-04-25Clinical Trial Update: A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma [Phase 1, Phase 2]
Phase I/IIa trial evaluating autologous SLAMF7 CAR-T cells for feasibility, safety, and antitumor activity in multiple myeloma.
-
CLINICAL_TRIALS trial_result · 2024-04-25Clinical Trial Update: Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma [Phase 1]
Phase 1 trial of an anti GM-2 monoclonal antibody for multiple myeloma has been terminated.
-
CLINICAL_TRIALS trial_result · 2024-04-22Clinical Trial Update: A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma
Pfizer's Elranatamab study in relapsed/refractory multiple myeloma has completed and posted results. The trial investigated the medicine in …
-
CLINICAL_TRIALS trial_result · 2024-04-19Clinical Trial Update: A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) [Phase 1]
Phase 1 study of belantamab mafodotin in relapsed/refractory multiple myeloma has completed, with results posted detailing safety, tolerabil…
-
CLINICAL_TRIALS trial_result · 2024-04-18Clinical Trial Update: A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 3]
Phase 3 trial comparing once-weekly versus twice-weekly carfilzomib in combination with lenalidomide and dexamethasone for relapsed or refra…
-
CLINICAL_TRIALS trial_result · 2024-04-12Clinical Trial Update: Stage I Multiple Myeloma Treatment [Phase 4]
A Phase 4 clinical trial update for stage I multiple myeloma has completed enrollment and treatment has been completed.
-
FDA approval · 2024-04-11FDA Approved: PLERIXAFOR — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved Amneal Pharmaceuticals LLC's supplemental application for plerixafor (generic) under an ANDA. This action approves a change…
-
CLINICAL_TRIALS trial_result · 2024-04-09Clinical Trial Update: Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for ICP-490 in relapsed/refractory multiple myeloma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2024-04-05Clinical Trial Update: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for CRD in carfilzomib-refractory multiple myeloma (Phase 1/2). Results have been posted as of 2024-04-05.
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: Bone Healing During Ninlaro Exposure [Phase 2]
Phase 2 clinical trial update examining bone healing during Ninlaro exposure in multiple myeloma has completed.
-
CLINICAL_TRIALS trial_result · 2024-04-03Clinical Trial Update: A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation [Phase 4]
A Phase 4 randomized, double-blind trial evaluating pentaisomaltose versus dimethyl sulfoxide for cryoprotection of autologous hematopoietic…
-
CLINICAL_TRIALS trial_result · 2024-04-02Clinical Trial Update: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
Results from Janssen's BCMA-targeted CAR-T therapy JNJ-68284528 in relapsed or refractory multiple myeloma were posted following a Phase 1/2…
-
CLINICAL_TRIALS trial_result · 2024-04-01Clinical Trial Update: Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients [Phase 1, Phase 2]
Phase 1/2 study of isatuximab as a single agent in Japanese relapsed and refractory multiple myeloma completed with results posted.